Skip to main content
. 2014 Oct 30;6(6):1560–1570. doi: 10.4161/19420862.2014.975099

Figure 6.

Figure 6.

DR5Nb1-tetra is potent in primary patient-derived colon and pancreatic tumor xenograft models. (A) TPAN1-IFA pancreatic tumor bearing mice treated for 4 weeks with PBS, DR5-A or DR5Nb1-tetra (N = 10/group). Waterfall plot of efficacy response across a panel of colon (B) or pancreatic (C) primary tumor models dosed weekly with DR5Nb1-tetra at 40 mg/kg. (B, C) Blue bars indicate tumor progression (%ΔT/ΔC >10%); green bars indicate stasis (10% >%ΔT/ΔC ≥−10%); red bars indicates regression (%ΔT/ΔC <−10%) (N = 4/group).